Market News

Company will use extension of Schedule I licence to start development of psychedelics-based pipeline to treat mental health disorders

The company will triple its capacity and workforce at its North Carolina site to increase its global capabilities and reach

The CDMO's Zydis technology will help the Canadian biotech to develop fast-acting, shorter-duration formulations of its potential therapy for treatment-resistant psychiatric disorders

Despite COVID-related challenges and supply chain issues, the CDMO's $240 million new facility is on target to open next year

The move ensures the service provider has the capacity to meet the needs of an evolving clinical market

US-headquartered company Kindeva seals deal for an R&D facility at Loughborough’s life sciences hub

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPhI webinar, sponsored by Stevanato Group.

The purchase will allow the company to add nine new customers to its growing CDMO business and 27 manufacturing suites

The enhancements will include installing the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which the FDA recently approved

During the next 12 months, demand for early-stage contract projects could quickly exceed supply

PsiVac has generated compelling efficacy data in killing a broad range of tumour cells, including head and neck, bladder, liver, pancreatic and ovarian

The strategic move will enable the injectables CDMO to support domestic companies that plan on bringing their molecules to the global market